How is arzerra administered?
Arzerra is given as an infusion into a vein. A healthcare provider will give you this injection. You may be given other medications to help prevent a reaction to the infusion. You may need to start using these medications up to 2 hours before the start of your ofatumumab infusion.
What class of drug is ofatumumab?
Ofatumumab injection is in a class of medications called monoclonal antibodies. It works by killing cancer cells.
How is ofatumumab administered?
Ofatumumab was first approved by the FDA in 2009 for the treatment of chronic lymphocytic leukemia (CLL) as an intravenous infusion with a high dose, administered by a healthcare provider.
Is ofatumumab FDA approved?
For multiple sclerosis, the therapy will be sold as Kesimpta by Novartis; it is administered by patients once a month through the Sensoready autoinjector pen.
Is Arzerra a chemotherapy?
Ofatumumab is the generic name for the trade chemotherapy drug Arzerra. In some cases, health care professionals may use the trade name Arzerra when referring to the generic drug name Ofatumumab. Drug Type: Ofatumumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.
What is Arzerra used for?
Arzerra is a brand-name prescription drug that’s FDA-approved to treat chronic lymphocytic leukemia (CLL). CLL is a type of cancer that affects your white blood cells. Arzerra is approved for use in adults with: CLL that has never been treated, and fludarabine-based treatment can’t be used.
Is Arzerra the same as Kesimpta?
Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.
Why was Arzerra withdrawn?
What were the reasons given by the company for withdrawing the application? In its letter notifying the Agency of the withdrawal of application, the company stated that its decision was based on the objections raised by the CHMP with regard to the design of the study and its patient population.
What is the difference between ofatumumab and ocrelizumab?
We mentioned that ofatumumab is a medication that’s self-administered by patients. Ocrelizumab is a medication that’s administered to the patient. Sometimes that may be a relative advantage in certain populations, when I actually know the patient had the treatment.
What is the brand name for ofatumumab?
Ofatumumab
| Monoclonal antibody | |
|---|---|
| Trade names | Arzerra, Kesimpta |
| Other names | HuMax-CD20, OMB157 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610009 |
What is the difference between Arzerra and Kesimpta?
What is ofatumumab used for?
Ofatumumab injection is used in combination with chlorambucil to treat a type of cancer of the white blood cells called chronic lymphocytic leukemia (CLL) in patients who have not received any treatments in the past.
How long do you take Kesimpta?
You won’t have any injections during week 3. Then, you’ll get one injection of Kesimpta at week 4. You’ll take your next injection at week 8. And you’ll continue using only one injection of Kesimpta each month after that.
What is ofatumumab made from?
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology.
Who makes Arzerra?
Novartis drug Arzerra® improved median progression-free survival by 54% in patients with relapsed chronic lymphocytic leukemia | Novartis.
Is Arzerra discontinued?
Patients with chronic lymphocytic leukemia (CLL) who are being treated with ofatumumab (Arzerra) will soon have to get their therapy through an oncology patient access program, as Novartis, the manufacturer, will no longer be selling the drug commercially for this indication.
What is the difference between rituximab and ocrelizumab?
Rituximab is a chimeric antibody, whilst ocrelizumab is a humanized IgG1 antibody that binds to a different, yet overlapping, epitope. Hence, ocrelizumab might be less immunogenic and elicit less anti-drug antibodies, that may contribute to a better safety profile and efficacy [8].
Is Ocrevus anti-CD20?
Anti-CD20 Monoclonal Antibody OCREVUS (ocrelizumab) is a recombinant humanized monoclonal antibody directed against CD20-expressing B cells.
Is ofatumumab a chemotherapy?
Is Ocrevus better than Kesimpta?
Kesimpta has an average rating of 6.4 out of 10 from a total of 13 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 25% reported a negative effect. Ocrevus has an average rating of 4.4 out of 10 from a total of 135 ratings on Drugs.com.